Tonix Pharmaceuticals Holding Corp [NASDAQ: TNXP] gained 2.97% or 0.01 points to close at $0.34 with a heavy trading volume of 38620946 shares.
The daily chart for TNXP points out that the company has recorded -96.70% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 9.70M shares, TNXP reached to a volume of 38620946 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Tonix Pharmaceuticals Holding Corp [TNXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNXP shares is $22.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNXP stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Noble Capital Markets have made an estimate for Tonix Pharmaceuticals Holding Corp shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 18, 2022. The new note on the price target was released on April 18, 2019, representing the official price target for Tonix Pharmaceuticals Holding Corp stock. Previously, the target price had yet another raise to $6, while ROTH Capital analysts kept a Buy rating on TNXP stock.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp is set at 0.10, with the Price to Sales ratio for TNXP stock in the period of the last 12 months amounting to 0.60. The Price to Book ratio for the last quarter was 0.08, with the Price to Cash per share for the same quarter was set at 0.19.
Trading performance analysis for TNXP stock
Tonix Pharmaceuticals Holding Corp [TNXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.01. With this latest performance, TNXP shares dropped by -41.33% in over the last four-week period, additionally sinking by -96.70% over the last 6 months – not to mention a drop of -98.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 22.77, with the RSI for the last a single of trading hit 21.79, and the three-weeks RSI is set at 23.58 for Tonix Pharmaceuticals Holding Corp [TNXP]. The present Moving Average for the last 50 days of trading for this stock 0.6686, while it was recorded at 0.3710 for the last single week of trading, and 7.5886 for the last 200 days.
Tonix Pharmaceuticals Holding Corp [TNXP]: A deeper dive into fundamental analysis
Tonix Pharmaceuticals Holding Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.72 and a Current Ratio set at 1.15.
Tonix Pharmaceuticals Holding Corp [TNXP]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Tonix Pharmaceuticals Holding Corp posted -58.56/share EPS, while the average EPS was predicted by analysts to be reported at -47.68/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -10.88. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TNXP.
An analysis of Institutional ownership at Tonix Pharmaceuticals Holding Corp [TNXP]
There are presently around $1.82%, or 1.85%% of TNXP stock, in the hands of institutional investors.
